Latest Content by PharmaCompass
KEY SERVICES
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.
About
Industry Trade Show
Attending
21-23 April, 2026
BIO International Conv...BIO International Convention
Industry Trade Show
Attending
22-25 June, 2026
Industry Trade Show
Attending
25-27 August, 2026
CONTACT DETAILS
Digital content 
CORPORATE CONTENT #SupplierSpotlight
NEWS #PharmaBuzz
13 May 2025
// PRESS RELEASE
06 May 2025
// PRESS RELEASE
29 Apr 2025
// PRESS RELEASE
04 Oct 2024
// PRESS RELEASE
17 Jun 2024
// PRESS RELEASE
13 Jun 2024
// PRESS RELEASE
Drugs in Development
Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : MEDOCHEMIE LTD
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Ethypharm Iberia Adds NEFOPAM to Portfolio
Details : The deal aims to advance Nefopam HCl, a miscellaneous product, targeting dopamine/serotonin/norepinephrine reuptake.
Product Name : Panagesic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 13, 2025
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Grunenthal
Deal Size : Undisclosed
Deal Type : Termination
Recivit® Rejoins Ethypharm’s Portfolio in France
Details : The deal aims to advance research on Fentanyl, a controlled substance targeting the Mu opioid receptor.
Product Name : Recivit
Product Type : Controlled Substance
Upfront Cash : Undisclosed
May 06, 2025
Lead Product(s) : Methoxyflurane
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Medical Developments International
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Medical Developments Intl. Licenses Penthrox® to Ethypharm for Distribution in France
Details : Through the licensing deal for Methoxyflurane, targeting GABA-A and Glycine receptors, the agreement aims to advance acute pain management.
Product Name : Penthrox
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 29, 2025
Lead Product(s) : Argatroban Monohydrate
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Recipient : Mitsubishi Tanabe Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Acquisition of Argatroban Business in Europe
Details : Ethypharm acquired Mitsubishi Tanabe's selective antithrombin agent Arganova (argatroban monohydrate) in Europe. It is indicated for the treatment of heparin-induced thrombocytopenia type II.
Product Name : Arganova
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 17, 2024
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Anbison
Deal Size : Undisclosed
Deal Type : Acquisition
Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China
Details : The acquisition will enable Ethypharm a full portfolio of Mesalazine forms, including a suppository form of Etiasa (mesalazine), used to treat IBD such as ulcerative colitis and Crohn's disease.
Product Name : Etiasa
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 13, 2024
Lead Product(s) : Morphine Sulfate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ethypharm Gains EU Approval for Morphine Immediate Release Tablets
Details : Company received marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine, an opioid receptor agonist for the management of severe pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 02, 2021
Lead Product(s) : Celecoxib
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Acquisition
Ethypharm Reinforces its Late-Stage R&D Pipeline with a Novel Acute Treatment of Migraine
Details : Ethypharm has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. Celecoxib is developed by D...
Product Name : Elyxyb
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 19, 2021
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Orphelia Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ORPHELIA, Ethypharm Sign Kigabeq® Licensing Deal for China
Details : Orphelia has granted Ethypharm exclusive rights under a license agreement to commercialize Kigabeq (vigabatrin) in China. Kigabeq is indicated as a first-line treatment for infantile spasms.
Product Name : Kigabeq
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 19, 2021
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 18, 2020
Lead Product(s) : Cholic Acid
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Laboratoires CTRS
Deal Size : Undisclosed
Deal Type : Agreement
Ethypharm, CTRS Partner to Register Orphacol® in China
Details : Under the agreement, CTRS has granted Ethypharm exclusive rights to distribute Orphacol (cholic acid) in China. It is indicated for the two rare inborn errors of primary bile acid synthesis.
Product Name : Orphacol
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Europe
Regulatory Info : Prescription
Registration Country : Denmark
Dosage Form : Injection Solution
Dosage Strength : 0.1mg/ml
Packaging :
Brand Name : Adrenaline \"Martindale Pharm...
Approval Date : 15-03-2017
Application Number : 28105871816
Regulatory Info : Prescription
Registration Country : Denmark
Regulatory Info : Prescription
Registration Country : Denmark
Dosage Form : Injection Solution
Dosage Strength : 1mg/ml
Packaging :
Brand Name : Adrenaline \"Ethypharm\"
Approval Date : 25-03-2019
Application Number : 28106180718
Regulatory Info : Prescription
Registration Country : Denmark
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Injectable Solution
Dosage Strength : 0.1mg/ml
Packaging :
Brand Name : Adrenaline Martindale Pharma
Approval Date : 27-02-2014
Application Number : 2.01E+13
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Injectable Solution
Dosage Strength : 1mg/ml
Packaging :
Brand Name : Adrenaline Ethypharm
Approval Date : 05-04-2019
Application Number : 2.02E+13
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Withdrawn
Registration Country : Malta
Dosage Form : Solution For Injection
Dosage Strength : 0.1MG/ML; 0.117MMOL/ML
Packaging :
Brand Name : Adrenaline (Epinephrine)
Approval Date : 2019-02-22
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta
Regulatory Info : Authorized
Registration Country : Spain
Dosage Form : Concentrate For Infusion Solut...
Dosage Strength : 100MG
Packaging :
Brand Name : Arganova
Approval Date : 18-11-2011
Application Number : 74548
Regulatory Info : Authorized
Registration Country : Spain
Regulatory Info : Prescription
Registration Country : Denmark
Dosage Form : Concentrate For Solution For I...
Dosage Strength : 100mg/ml
Packaging :
Brand Name : Novastan
Approval Date : 03-01-2006
Application Number : 28103782405
Regulatory Info : Prescription
Registration Country : Denmark
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Concentrate For Solution For I...
Dosage Strength : 100mg/ml
Packaging :
Brand Name : Novastan
Approval Date : 15-10-2004
Application Number : 2.00E+13
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Concentrate For Solution For I...
Dosage Strength : 100mg/ml
Packaging :
Brand Name : Novastan Multidose
Approval Date : 18-09-2009
Application Number : 2.01E+13
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Infusion Solution
Dosage Strength : 1mg/ml
Packaging :
Brand Name : Novastan
Approval Date : 19-05-2016
Application Number : 2.01E+13
Regulatory Info : Approved
Registration Country : Sweden
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
Regulatory Info :
Registration Country : France
Dosage Form : Ampoule
Brand Name :
Dosage Strength : 200MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Regulatory Info :
Registration Country : France
Dosage Form : Vial
Brand Name :
Dosage Strength : 250MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Regulatory Info :
Registration Country : France
Dosage Form : Ampoule
Brand Name :
Dosage Strength : 1MG/1ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Regulatory Info :
Registration Country : France
Dosage Form : Pre-filled Syringe
Brand Name :
Dosage Strength : 1MG/10ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Regulatory Info :
Registration Country : France
Dosage Form : Powder for Solution for Infu...
Brand Name :
Dosage Strength : 20MCG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Regulatory Info :
Registration Country : France
Dosage Form : Capsule
Brand Name :
Dosage Strength : 80MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Regulatory Info :
Registration Country : France
Dosage Form : Capsule
Brand Name :
Dosage Strength : 125MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Regulatory Info :
Registration Country : France
Dosage Form : Vial
Brand Name :
Dosage Strength : 37.5MG/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Regulatory Info :
Registration Country : France
Dosage Form : Ampoule
Brand Name :
Dosage Strength : 6.75MG/0.9ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Regulatory Info :
Registration Country : France
Dosage Form : Ampoule
Brand Name :
Dosage Strength : 600MCG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Liquid
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Suspension
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lyophilization
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Solution
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Granule / Pellet
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Injectable / Parenteral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Formulation Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]KEY SERVICES
TOP RANKED SUPPLIER FOR:
GDUFA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Others
THIRD-PARTY AUDIT
Country : France
City/Region : Le Grand-Quevilly
Audit Date : 2025-06-20
Audit Type : On-Site
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Ethypharm
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.
